高尿酸血症
琥珀酸
小檗碱
尿酸
降级(电信)
化学
脆弱类杆菌
生物化学
计算机科学
电信
抗生素
作者
Li‐Bin Pan,Ru Feng,Jiachun Hu,Hang Yu,Qian Tong,Xinyu Yang,Jian‐Ye Song,Hui Xu,Mengliang Ye,Zhengwei Zhang,Jie Fu,Haojian Zhang,Jin‐Yue Lu,Zhao Zhai,Jingyue Wang,Yi Zhao,Hengtong Zuo,Hui Xiang,Jian‐Dong Jiang,Yan Wang
标识
DOI:10.1016/j.apsb.2025.08.009
摘要
, significantly reduced uric acid levels. Subsequent cell and animal experiments revealed that the intestinal metabolite, succinic acid, regulated the upstream uric acid synthesis pathway in the liver by inhibiting adenosine monophosphate deaminase 2 (AMPD2), an enzyme responsible for converting adenosine monophosphate (AMP) to inosine monophosphate (IMP). This inhibition resulted in a decrease in IMP levels and an increase in phosphate levels. The reduction in IMP led to a decreased downstream production of hypoxanthine, xanthine, and uric acid. BBR also demonstrated excellent renoprotective effects, improving nephropathy associated with hyperuricemia. In summary, BBR has the potential to be an effective treatment for hyperuricemia through the gut-liver axis.
科研通智能强力驱动
Strongly Powered by AbleSci AI